Recent Accomplishments & 2008 Highlights Include:
- Initiation of development activities to support regulatory filings for new Bitter Blockers
- Receipt of GRAS (Generally Recognized As Safe) designation for Sucralose Enhancer S2383, which allows commercialization in the U.S. and elsewhere
- New commercialization agreement for S2383 with Firmenich SA
- Continued activities to support regulatory filings for Sucrose (table sugar) Enhancer S6973
SAN DIEGO, CA, February 12, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX), a company focused on using proprietary taste receptor-based technologies to discover novel flavor ingredients for the food, beverage, and ingredient supply industries, today reported financial results for the fourth quarter and year ended December 31, 2008. Senomyx ended 2008 with more than $40 million in cash, cash equivalents, and investments available-for-sale and no debt.
"2008 was an important year for Senomyx, with both scientific and business accomplishments that culminated in the receipt of a GRAS (Generally Recognized As Safe) designation for our sucralose enhancer, S2383, and a new collaboration with Firmenich for the commercialization of S2383 in the US and elsewhere," said Kent Snyder, President and Chief Executive Officer of the Company. "Sucralose is a widely used high-intensity sweetener and we believe Firmenich has the ability to drive worldwide market acceptance and maximize the long-term revenue potential for S2383.
"Senomyx's progress in our Sweet Enhancer, Salt Enhancer, and Bitter Blocker programs during 2008 led to the extension and/or expansion of all the collaborative agreements that were due for renewal, as well as milestone payments from two partners," Snyder noted. "We also repor
|SOURCE Senomyx, Inc.|
Copyright©2009 PR Newswire.
All rights reserved